iPSC-Derived CD4+ T Cells via RUNX3 Knockout and RUNX1 Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing CD4+ T cells from pluripotent stem cells are inefficient and unstable, particularly in inducing CD4+ T cells without regulatory T cell characteristics, limiting their use in immunotherapy.
Innovation Solution
A method involving gene manipulation of pluripotent stem cells, specifically knocking out RUNX3, ZBTB7B, SOCS1, SOCS3, and GIMAP5, and/or overexpressing RUNX1, to induce CD4+ T cells with Th1 cell phenotype and antigen-specific cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If iPSCs are induced to differentiate into T cells using conventional methods, then large amounts of T cells can be produced, but the induction of CD4+ T cells is unstable and requires artificial introduction of the CD4 gene
Solution Approach 1:
The invention changes the genetic parameters of iPSCs by knocking out RUNX3 and overexpressing RUNX1, which fundamentally alters the differentiation trajectory to stably produce CD4+ T cells without requiring artificial CD4 gene introduction. This parameter change in gene expression profiles enables both high yield and stable induction of CD4+ T cells.
Solution Approach 2:
The invention extracts and removes the harmful factor (RUNX3 gene) that prevents stable CD4+ T cell differentiation. By knocking out RUNX3, the patent eliminates the obstacle that causes unstable induction, allowing natural differentiation into CD4+ T cells to proceed efficiently and reliably.
2Quantity of substance
If conventional differentiation methods are used, then T cells can be produced, but regulatory T cells are generated which limit therapeutic application
Solution Approach 1:
The invention changes the differentiation parameters by manipulating RUNX3 and RUNX1 expression, which shifts the lineage commitment from regulatory T cell (Foxp3+) to non-regulatory CD4+ T cell (Foxp3-). This parameter change produces T cells with enhanced therapeutic versatility for cancer immunotherapy.
Solution Approach 2:
The invention converts the harmful effect of RUNX3 (which drives regulatory T cell formation that limits therapy) into a benefit by knocking it out. This eliminates the generation of immunosuppressive regulatory T cells while maintaining high productivity of therapeutic CD4+ T cells.
3Reliability
If gene manipulation is performed to achieve stable CD4+ T cell production, then therapeutic efficacy is improved, but process complexity increases
Solution Approach 1:
The invention uses gene manipulation to change the expression parameters of RUNX3 and RUNX1, which establishes stable CD4+ T cell differentiation. While this does increase process complexity, the targeted approach of modifying only two key genes provides a manageable and effective solution compared to attempting to control multiple differentiation factors simultaneously.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method for producing a CD4 positive T cell, including a step of knocking out one or more genes selected from the group consisting of RUNX3, ZBTB7B, SOCS1, SOCS3, and GIMAPS and/or overexpressing the RUNX1 gene in a human induced pluripotent stem cell (iPSC), a CD4 positive T cell that can be obtained by the method, and a pharmaceutical composition such as immunotherapeutic agent and the like containing the cell.